K. Cw and B. Ao, Androgens, antiandrogens and androgen receptor abnormalities, Eur Urol, vol.29, issue.2, pp.78-82, 1996.

S. Hi and K. Wk, Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer, J Clin Oncol, vol.11, issue.8, pp.1566-72, 1993.

D. La, T. A. , R. M. , and C. Mw, beta- Catenin-related Anomalies in Apoptosis-resistant and Hormone-refractory Prostate Cancer Cells, Clin Cancer Res, vol.9, issue.5, pp.1801-1808, 2003.

C. Dr and I. Wb, Beta-catenin signaling in prostate cancer: an early perspective, Endocr Relat Cancer, vol.10, issue.4, pp.537-60, 2003.

B. Yj, P. F. , and F. Wg, Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP, Proc Natl Acad Sci U S A, vol.91, 1994.

R. Aj, P. H. , C. Mw, D. Ml, S. Js et al., Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo, Cancer Res, vol.55, pp.4438-4483, 1995.

P. M. Nickerson-t and H. H. , Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5, Endocrinology, vol.139, issue.2, pp.807-817, 1998.
DOI : 10.1210/endo.139.2.5912

S. Ja, S. Dm, and R. A. , Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glyco- protein-2 (clusterin), Cancer Res, vol.55, issue.11, pp.2431-2438, 1995.

S. Sm and S. J. Kozlowski-jm, Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin), Prostate, vol.39, issue.2, pp.87-93, 1999.

B. R. , M. D. , H. Sg, S. F. , and A. Dc, p53 is mutated in a subset of advanced-stage prostate cancers, Cancer Res, vol.53, issue.14, pp.3369-73, 1993.

D. Marzo-am, S. J. Bradshaw-c, E. Ji, and M. Gj, CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture, The Prostate, vol.26, issue.3, pp.162-170, 1998.
DOI : 10.1002/(SICI)1097-0045(19980215)34:3<162::AID-PROS2>3.0.CO;2-K

D. Jt, S. Tw, and H. Er, PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate, Oncogene, vol.17, issue.15, pp.1979-82, 1998.

M. Me, S. P. , P. S. Kaplan-i, L. M. , and S. Wr, Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage, Cancer Res, vol.59, issue.17, pp.4291-4297, 1999.

E. S. and Y. G. Harper-jw, Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis, Mod Pathol, vol.12, issue.8, pp.751-756, 1999.

A. and S. Mm, Molecular genetics of prostate cancer, Genes Dev, vol.14, pp.2410-2444, 2000.

S. M. and B. L. Srikantan-v, ANX7, a candidate tumor suppressor gene for prostate cancer, Proc Natl Acad Sci U S A, vol.98, issue.8, pp.4575-80, 2001.

C. Mw, V. F. , and D. La-taille-a, The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells, Oncogene, vol.21, issue.51, pp.7861-71, 2002.

K. Y. and O. A. Shibata-t, c-erbB-2 gene product directly associates with beta-catenin and plakoglobin, Biochem Biophys Res Commun, vol.208, issue.3, pp.1067-72, 1995.

P. Polakis, Wnt Signaling in Cancer, Cold Spring Harbor Perspectives in Biology, vol.4, issue.5, pp.1837-51, 2000.
DOI : 10.1101/cshperspect.a008052

G. Rh and C. H. Van-es-jh, Caught up in a Wnt storm: Wnt signaling in cancer, Biochim Biophys Acta, vol.1653, issue.1, pp.1-24, 2003.

H. Lg, H. Sm, and L. Cs, Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer, Int J Cancer, vol.113, issue.3, pp.415-437, 2005.

V. Hj, T. Ci, and G. Ep, Beta-catenin mutations in human prostate cancer, Cancer Res, vol.58, issue.12, pp.2520-2523, 1998.

C. Dr, E. Cm, S. J. , B. Gs, and I. Wb, Detection and analysis of beta-catenin mutations in prostate cancer, Prostate, vol.45, issue.4, pp.323-357, 2000.

K. V. Barker-n and . Morin-pj, Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma, Science, vol.275, issue.5307, pp.1784-1791, 1997.

C. S. , G. Dc, and Y. Z. , Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factormediated transcription, J Cell Biol, vol.152, issue.1, pp.87-96, 2001.

Y. X. , C. Mw, and T. S. , A human-and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells, Cancer Res, vol.65, issue.12, pp.5263-71, 2005.

P. Abrahamsson, Neuroendocrine differentiation in prostatic carcinoma, The Prostate, vol.14, issue.2, pp.135-183, 1999.
DOI : 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S

R. P. and B. F. Zamora-aj, Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines, Cancer Res, vol.61, issue.3, pp.1196-206, 2001.

C. O. , V. Jm, C. , and B. P. , Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors, Prostate Suppl, vol.8, pp.43-51, 1998.

K. D. , T. Tc, L. Gr, and S. Pt, Elevated plasma chromogranin-A concentrations in prostatic carcinoma, J Urol, vol.146, issue.2, pp.358-61, 1991.

H. Wj, G. Dr, W. Es, F. Wk, J. et al., Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model, Prostate, vol.60, issue.2, pp.77-90, 2004.

D. Pinieux-g, L. Me, and P. , Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic Approach, The American Journal of Pathology, vol.159, issue.2, pp.753-64, 2001.
DOI : 10.1016/S0002-9440(10)61746-4

W. Me and A. R. Tsai-mj, Androgen Receptor Represses the Neuroendocrine Transdifferentiation Process in Prostate Cancer Cells, Mol Endocrinol, 2003.